A new 4-dimensional software program promises to improve the treatment of lung cancer by allowing doctors to take the movement of breathing into account when administering radiotherapy, French researchers announced today at the 2^nd European Lung Cancer Conference in Geneva, Switzerland.

Some lung tumours shift their position as patients inhale and exhale. The amount of movement depends on where they are in the lung. For example, lesions in the lower lobes may move up to 4 cm.

This movement poses a challenge for doctors treating the cancer with radiotherapy. If they use too small an irradiation field, the tumour can move so far that it is missed by the treatment. To avoid this, standard radiotherapy uses large radiation fields to take into account the respiratory movements, but in doing so can damage large areas of healthy lung tissue.

A newer approach, called 'breathing-adapted radiotherapy' (BART) allows doctors to reduce the amount of radiation delivered, and improve the chance of hitting the tumour, by timing delivery to a particular moment of the respiratory cycle.

"One of the main problems with BART is how to choose the optimal respiratory phase in which to treat the patient," explains Dr Nicolas Peguret from Hôpitau Universitaires de Genève. "This phase is basically unknown and may be in deep inspiration, in expiration or even in a third respiratory phase somewhere between. It may vary from one patient to another because of the variation in tumour localisation and in movements of the tumour and of other nearby organs."

Dr Peguret and colleagues have developed software which allows doctors to determine a moment during the respiratory cycle with an optimal tumour position for radiotherapy. "By applying this software together with BART, it may be possible not only to reduce the radiation fields but also to adapt the radiation volume taking into account the varying positions of the tumour and the organs at risk."

The technique involves two steps: first, for each patient, a 4-dimensional computed tomography (4D CT) scan is performed, recording a set of CT slices for each of 10 respiratory phases. This technique is already well known in the medical world, particularly in the field of cardiology. Second, the new software helps the radiation oncologist to determine if there is a respiratory phase that is most convenient for radiotherapy, based on criteria that have been established by a panel of oncologists.

"The software doesn’t require any special equipment and doesn’t cause any additional cost," Dr Peguret said. "However, it is important to have a 4D CT available to be able to acquire synchronised image sets, as well as a system that allows synchronisation of the thoracic movements during radiotherapy."

"The software will never replace the radiation oncologist," he added. "It simply provides the doctor with information about the movement of the tumour. Depending on the oncologist’s clinical objectives, he or she will choose the optimal phase for radiotherapy in an individual patient. In this way, our software transforms the information provided by 4D CT into a real benefit for the patient."

At the conference, Dr Peguret will report that the system may help to increase the dose to the target.

"Local control and overall survival depend on the radiation dose that can be delivered to the tumour with a relative sparing of the organs at risk," he said. "To our knowledge, there is no other similar software on the market. 4D CT and the techniques of BART are still underutilised in oncology. This work might allow its dispersion to other centres with the ultimate aim of improving the survival of the patients."

A Phase II clinical trial is currently underway and results are expected early in 2011.

Source: ESMO